News | November 07, 2025
AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Subscribe To Our Newsletter & Stay Updated
